EA202090370A1 - Двухрежимная радиоактивная метка и радиотерапевтическое средство - Google Patents
Двухрежимная радиоактивная метка и радиотерапевтическое средствоInfo
- Publication number
- EA202090370A1 EA202090370A1 EA202090370A EA202090370A EA202090370A1 EA 202090370 A1 EA202090370 A1 EA 202090370A1 EA 202090370 A EA202090370 A EA 202090370A EA 202090370 A EA202090370 A EA 202090370A EA 202090370 A1 EA202090370 A1 EA 202090370A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sifa
- radiotherapeutic
- mode
- radioactive
- radioactive tag
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17183795 | 2017-07-28 | ||
| PCT/EP2018/070533 WO2019020831A1 (en) | 2017-07-28 | 2018-07-30 | AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090370A1 true EA202090370A1 (ru) | 2020-05-25 |
Family
ID=59501286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090370A EA202090370A1 (ru) | 2017-07-28 | 2018-07-30 | Двухрежимная радиоактивная метка и радиотерапевтическое средство |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11413360B2 (enExample) |
| EP (3) | EP4000640A1 (enExample) |
| JP (2) | JP7059372B2 (enExample) |
| KR (2) | KR102752620B1 (enExample) |
| CN (1) | CN111132700B (enExample) |
| AU (2) | AU2018308699B2 (enExample) |
| BR (1) | BR112020001785A2 (enExample) |
| CA (1) | CA3071315A1 (enExample) |
| DK (1) | DK3658194T3 (enExample) |
| EA (1) | EA202090370A1 (enExample) |
| ES (1) | ES3011272T3 (enExample) |
| FI (1) | FI3658194T3 (enExample) |
| HU (1) | HUE070098T2 (enExample) |
| IL (2) | IL272291B2 (enExample) |
| MX (2) | MX2020000352A (enExample) |
| PL (1) | PL3658194T3 (enExample) |
| PT (1) | PT3658194T (enExample) |
| SG (1) | SG11202000725WA (enExample) |
| WO (1) | WO2019020831A1 (enExample) |
| ZA (1) | ZA202000467B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3658194T3 (pl) | 2017-07-28 | 2025-09-15 | Technische Universität München | Radioznacznik i środki radioterapeutyczne o podwójnym trybie działania |
| KR20210153036A (ko) * | 2019-01-30 | 2021-12-16 | 테크니쉐 우니베르지테트 뮌헨 | 암 진단 영상화제들 |
| JP7421232B2 (ja) * | 2019-01-30 | 2024-01-24 | テクニシェ ユニバーシタット ミュンヘン | フッ化ケイ素アクセプタ置換放射性医薬品とその前駆体 |
| FI3917626T3 (fi) | 2019-01-30 | 2023-08-17 | Univ Muenchen Tech | Psma:ta sitova kaksimuotoinen radiomerkkiaine ja terapeuttinen aine |
| CN112168978B (zh) * | 2019-07-03 | 2022-01-11 | 北京大学 | 一种抗体偶联药物及其药物组合物与应用 |
| CA3155519A1 (en) * | 2019-10-29 | 2021-05-06 | Steve Shih-Lin Huang | Psma-targeting imaging agents |
| CN113350531A (zh) * | 2020-03-02 | 2021-09-07 | 上海核力星医药科技有限公司 | 前列腺特异性膜抗原结合配体偶联物及其应用 |
| GB202005282D0 (en) * | 2020-04-09 | 2020-05-27 | Blue Earth Diagnostics Ltd | Pharmaceutical Formulations |
| WO2022018264A1 (en) | 2020-07-23 | 2022-01-27 | Technische Universität München | Silicon-containing ligand compounds |
| CA3191472A1 (en) | 2020-09-03 | 2022-03-10 | Curium Us Llc | Radiolabeling and formulation for scale up of 64cu-dotatate |
| EP4023250A1 (en) * | 2021-01-04 | 2022-07-06 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| AU2022219543A1 (en) | 2021-02-15 | 2023-08-17 | Technische Universität München | Dual mode radiotracer and therapeutics |
| AU2022273184A1 (en) * | 2021-05-14 | 2023-10-12 | Technische Universität München | Radiopharmaceutical somatostatin receptor ligands and precursors thereof |
| GB202108779D0 (en) | 2021-06-18 | 2021-08-04 | Blue Earth Diagnostics Ltd | Si-at therapeutic/diagnostic compounds |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| AU2022323741A1 (en) * | 2021-08-05 | 2024-02-01 | Technische Universität München | Ligand compounds comprising a chelating group as a bridging group |
| GB202113646D0 (en) | 2021-09-24 | 2021-11-10 | Blue Earth Diagnostics Ltd | Method of preparation of 18F labelled silyl-fluoride compounds |
| CN114671806B (zh) * | 2022-04-08 | 2024-03-01 | 上海如絮生物科技有限公司 | 一种亲水性吡啶衍生物、中间体、其制备方法及应用 |
| GB202207372D0 (en) | 2022-05-19 | 2022-07-06 | Blue Earth Diagnostics Ltd | Synthesis of fluorosilyl compounds |
| WO2024023332A1 (en) | 2022-07-29 | 2024-02-01 | Technische Universität München | Silicon-based fluoride acceptor groups for radiopharmaceuticals |
| WO2024054226A1 (en) * | 2022-09-06 | 2024-03-14 | Hoang Ba Xuan | Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment |
| EP4631959A3 (en) * | 2022-09-20 | 2025-12-17 | Technische Universität München, in Vertretung des Freistaats Bayern | Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| CN120417945A (zh) * | 2022-11-14 | 2025-08-01 | 阿克提斯肿瘤学公司 | 肾脏中小蛋白滞留的减少 |
| WO2025072791A2 (en) | 2023-09-29 | 2025-04-03 | Aktis Oncology, Inc. | Miniproteins, conjugates & uses thereof |
| GB202316239D0 (en) | 2023-10-24 | 2023-12-06 | Blue Earth Diagnostics Ltd | Therapeutic combination |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995001346A1 (en) * | 1993-06-30 | 1995-01-12 | Akzo Nobel N.V. | Chelating compounds |
| JP2005519861A (ja) * | 2001-07-27 | 2005-07-07 | ターゲサム・インコーポレーテッド | 治療剤及び撮像剤としての脂質構築物 |
| CN102626522B (zh) * | 2012-04-12 | 2014-09-10 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
| US10799605B2 (en) * | 2014-06-10 | 2020-10-13 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| WO2016062370A1 (en) | 2014-10-20 | 2016-04-28 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US20160287730A1 (en) * | 2015-03-31 | 2016-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Labeled evans blue dye derivative for in vivo serum albumin labeling |
| JP7266365B2 (ja) * | 2015-05-26 | 2023-04-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 分子および生体分子の１８ｆ標識化に有用な新規な複素芳香環フッ化ケイ素アクセプタおよびその調製方法 |
| PL3658194T3 (pl) | 2017-07-28 | 2025-09-15 | Technische Universität München | Radioznacznik i środki radioterapeutyczne o podwójnym trybie działania |
| CN116617421A (zh) * | 2017-12-11 | 2023-08-22 | 慕尼黑工业大学 | 用于诊断和/或治疗的药物组合物 |
| FI3917626T3 (fi) | 2019-01-30 | 2023-08-17 | Univ Muenchen Tech | Psma:ta sitova kaksimuotoinen radiomerkkiaine ja terapeuttinen aine |
| KR20210153036A (ko) | 2019-01-30 | 2021-12-16 | 테크니쉐 우니베르지테트 뮌헨 | 암 진단 영상화제들 |
-
2018
- 2018-07-30 PL PL18743540.9T patent/PL3658194T3/pl unknown
- 2018-07-30 IL IL272291A patent/IL272291B2/en unknown
- 2018-07-30 PT PT187435409T patent/PT3658194T/pt unknown
- 2018-07-30 AU AU2018308699A patent/AU2018308699B2/en active Active
- 2018-07-30 ES ES18743540T patent/ES3011272T3/es active Active
- 2018-07-30 BR BR112020001785-0A patent/BR112020001785A2/pt unknown
- 2018-07-30 EP EP22150556.3A patent/EP4000640A1/en not_active Withdrawn
- 2018-07-30 SG SG11202000725WA patent/SG11202000725WA/en unknown
- 2018-07-30 US US16/634,759 patent/US11413360B2/en active Active
- 2018-07-30 FI FIEP18743540.9T patent/FI3658194T3/fi active
- 2018-07-30 KR KR1020207005589A patent/KR102752620B1/ko active Active
- 2018-07-30 CA CA3071315A patent/CA3071315A1/en active Pending
- 2018-07-30 EP EP24184312.7A patent/EP4424378A3/en active Pending
- 2018-07-30 IL IL318092A patent/IL318092A/en unknown
- 2018-07-30 DK DK18743540.9T patent/DK3658194T3/da active
- 2018-07-30 CN CN201880062949.0A patent/CN111132700B/zh active Active
- 2018-07-30 EA EA202090370A patent/EA202090370A1/ru unknown
- 2018-07-30 JP JP2020526688A patent/JP7059372B2/ja active Active
- 2018-07-30 EP EP18743540.9A patent/EP3658194B1/en active Active
- 2018-07-30 KR KR1020247006169A patent/KR20240027896A/ko not_active Ceased
- 2018-07-30 WO PCT/EP2018/070533 patent/WO2019020831A1/en not_active Ceased
- 2018-07-30 HU HUE18743540A patent/HUE070098T2/hu unknown
- 2018-07-30 MX MX2020000352A patent/MX2020000352A/es unknown
-
2020
- 2020-01-10 MX MX2023007914A patent/MX2023007914A/es unknown
- 2020-01-23 ZA ZA2020/00467A patent/ZA202000467B/en unknown
-
2022
- 2022-04-12 JP JP2022065524A patent/JP2022101601A/ja active Pending
- 2022-06-24 US US17/849,297 patent/US12390540B2/en active Active
-
2024
- 2024-01-24 AU AU2024200440A patent/AU2024200440B2/en active Active
- 2024-11-15 US US18/948,808 patent/US12453787B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090370A1 (ru) | Двухрежимная радиоактивная метка и радиотерапевтическое средство | |
| EA202192045A1 (ru) | Средства для диагностической визуализации ракового заболевания | |
| PH12018500062A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| CY1123884T1 (el) | Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων | |
| CY1123995T1 (el) | Αντισωματα ειδικα για υπερφωσφορυλιωμενη ταυ και μεθοδοι χρησης αυτων | |
| EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
| ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| CR20210556A (es) | Quelantes macrocíclicos y métodos de uso de estos | |
| MY200335A (en) | Bispecific binding proteins and uses thereof | |
| CU20170169A7 (es) | Anticuerpos de factor xi | |
| EA201992595A1 (ru) | Усиление фармакокинетики бифункциональных хелатов и их применения | |
| BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
| BR112021011729A2 (pt) | Tubulisinas e conjugados de proteína-tubulisina | |
| NZ749058A (en) | Preparation of 212pb labeled monoclonal antibodies | |
| EA201990895A1 (ru) | Антитела к о1 и варианты их применения | |
| EA201992318A1 (ru) | Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин | |
| MX2019004371A (es) | Anticuerpos que se unen a la proteina de envoltura del virus zika y usos de los mismos. | |
| EA202090116A1 (ru) | Композиции, содержащие конъюгаты каннабиноидного аналога, и способы применения | |
| EA201992315A1 (ru) | Композиции и способы для лечения рака легкого | |
| EA202091978A1 (ru) | Биспецифические связывающие агенты и варианты их применения | |
| CR20190012A (es) | Anticuerpos específicos para la tauy hiperfosforilada y sus métodos de uso | |
| EA201992747A1 (ru) | Антитела к fam19a5 и их применение | |
| EA201991330A1 (ru) | Способы лечения рака с помощью антител к tim-3 |